Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 3/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | FASN | P49327 | 3/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5176401 | 0.86 | KCNH2 (0.47) | PGRNAAALRRK2FASNENPP3 | |
| SCHEMBL4104449 | 0.85 | PGR (0.40) | PGRLRRK2CYP11B1CYP11B2FASN | |
| SCHEMBL508704 | 0.83 | KCNH2 (0.52) | PGRNAAALRRK2FASNENPP3 | |
| SCHEMBL4104852 | 0.80 | ENPP3 (0.55) | PGRNAAACYP11B1CYP11B2DHODH | |
| SCHEMBL509046 | 0.71 | KCNH2 (0.45) | LRRK2CYP11B1CYP11B2FASN | |
| SCHEMBL4751277 | 0.71 | AR (0.40) | FASNHRH3 | |
| SCHEMBL4105432 | 0.71 | AR (0.38) | LRRK2HRH3 | |
| SCHEMBL4812237 | 0.70 | KCNH2 (0.67) | PGR | |
| SCHEMBL4105032 | 0.68 | LRRK2 (0.37) | LRRK2FASN | |
| SCHEMBL4748718 | 0.68 | PKM (0.35) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099209-A1 | Compounds Useful in Therapy | PFIZER INC | 2009-04-16 | — | — | US | disclosed |
| US-7482375-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1874732-A1 | PYRAZOLE DERIVATIVES AS PROGESTERONE RECEPTOR ANTAGONISTS | Pfizer Limited (GB) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006111856-A1 | PYRAZOLE DERIVATIVES AS PROGESTERONE RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 2006-10-26 | — | — | WO | disclosed |
| US-20060241125-A1 | Compounds useful in therapy | BRADLEY PAUL A | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241125-A1 | Compounds useful in therapy | CBR3, GPER1, CBR1 | PGR 57/4885NAAA 3745/4885LRRK2 3396/4885 |
| US-20090099209-A1 | Compounds Useful in Therapy | CBR3, CBR1, GPER1 | PGR 87/4885NAAA 3904/4885LRRK2 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.